MiniMed (MMED) launched its Flex insulin pump system in the US, the company said Wednesday.
The system is cleared by the US Food and Drug Administration for people aged 7 and older with type 1 diabetes and adults with insulin-requiring type 2 diabetes, MiniMed said.
The Flex system is the company's first app-controlled insulin pump and is paired at launch with the Simplera Sync, a disposable continuous glucose monitoring sensor, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.